ProShare Advisors LLC Has $2.59 Million Stock Position in Hologic, Inc. $HOLX

ProShare Advisors LLC cut its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.7% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 39,671 shares of the medical equipment provider’s stock after selling 2,843 shares during the quarter. ProShare Advisors LLC’s holdings in Hologic were worth $2,585,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of HOLX. Allspring Global Investments Holdings LLC raised its position in Hologic by 473.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider’s stock valued at $111,180,000 after purchasing an additional 1,405,085 shares during the last quarter. Nuance Investments LLC increased its stake in shares of Hologic by 623.7% in the first quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider’s stock valued at $66,794,000 after buying an additional 931,920 shares during the period. Invesco Ltd. raised its holdings in Hologic by 18.8% in the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock valued at $298,655,000 after buying an additional 764,573 shares during the last quarter. Nuveen LLC acquired a new stake in Hologic during the 1st quarter worth approximately $30,317,000. Finally, Sound Shore Management Inc. CT grew its holdings in Hologic by 42.6% during the 1st quarter. Sound Shore Management Inc. CT now owns 1,383,628 shares of the medical equipment provider’s stock worth $85,467,000 after acquiring an additional 413,403 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

HOLX has been the topic of several analyst reports. Leerink Partners boosted their price objective on shares of Hologic from $70.00 to $78.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 21st. Evercore ISI set a $78.00 price target on Hologic and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Morgan Stanley boosted their price target on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Raymond James Financial cut shares of Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Finally, Needham & Company LLC restated a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $79.77.

Insider Activity at Hologic

In other Hologic news, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the sale, the director owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. This trade represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Stephen P. Macmillan sold 138,358 shares of the business’s stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at approximately $82,682,769.28. This represents a 10.08% decrease in their position. The SEC filing for this sale provides additional information. 1.88% of the stock is currently owned by corporate insiders.

Hologic Stock Down 0.1%

Shares of NASDAQ HOLX opened at $74.15 on Friday. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The firm has a market cap of $16.49 billion, a PE ratio of 30.77, a P/E/G ratio of 2.54 and a beta of 0.65. The company’s fifty day simple moving average is $69.76 and its 200 day simple moving average is $65.73. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $80.31.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.03. The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.03 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.01 earnings per share. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.